KalVista Pharmaceuticals presented compelling new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, underscoring the critical ongoing need for effective on-demand treatments for Hereditary Angioedema (HAE) attacks, even among patients consistently receiving long-term prophylaxis (LTP). The interim analysis from the KONFIDENT-S study showcased sebetralstat, KalVista's investigational oral on-demand therapy, demonstrating a median time to symptom relief of just 1.3 hours for HAE attacks, irrespective of the patient's specific LTP (including berotralstat, lanadelumab, or C1 inhibitor). This highlights sebetralstat's potential as a rapid and reliable option, easily administered by patients. Furthermore, accompanying real-world data revealed that nearly half of HAE patients struggle with adherence to their LTP regimens, leading to more frequent breakthrough attacks requiring on-demand intervention. These combined findings strongly reinforce the importance of having an efficacious and convenient oral on-demand treatment like sebetralstat to complement existing HAE management strategies and address the persistent challenge of breakthrough attacks and non-adherence.